Veloxis Pharmaceuticals A/S Stock

Equities

VELO

DK0060048148

Pharmaceuticals

Delayed Nasdaq Copenhagen 5-day change 1st Jan Change
- DKK -.--% Intraday chart for Veloxis Pharmaceuticals A/S -.--% -0.50%

Financials

Sales 2017 30.17M 4.39M 5.99M Sales 2018 39.49M 5.74M 7.84M Capitalization 3.75B 546M 746M
Net income 2017 -9M -1.31M -1.79M Net income 2018 -5M -727K -993K EV / Sales 2017 49.4 x
Net Debt 2017 18.05M 2.63M 3.58M Net Debt 2018 29.38M 4.27M 5.84M EV / Sales 2018 95.8 x
P/E ratio 2017
-154 x
P/E ratio 2018
-708 x
Employees -
Yield 2017 *
-
Yield 2018
-
Free-Float 10%
More Fundamentals * Assessed data
Dynamic Chart
Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) CI
Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA. CI
Veloxis Pharmaceuticals A/S Announces Board Appointments CI
Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from OMX Nordic All-Share Index CI
Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index CI
Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index CI
Asahi Kasei Pharma Denmark A/S completed the acquisition of Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others. CI
Transcript : Asahi Kasei Pharma Denmark A/S, Veloxis Pharmaceuticals A/S - M&A Call
Asahi Kasei Pharma Denmark A/S entered into a transaction agreement to acquire Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others for DKK 9.2 billion. CI
Transcript : Veloxis Pharmaceuticals A/S, Q3 2019 Earnings Call, Nov 13, 2019
Veloxis Pharmaceuticals A/S Reports Earnings Results for the Third Quarter Ended September 30, 2019 CI
Veloxis Pharmaceuticals A/S Increases Earnings Guidance for 2019 CI
Veloxis Pharmaceuticals A/S(CPSE:VELO) added to S&P Global BMI Index CI
Transcript : Veloxis Pharmaceuticals A/S, Q2 2019 Earnings Call, Aug 09, 2019
Veloxis Pharmaceuticals A/S Reports Earnings Results for the Second Quarter Ended June 30, 2019 CI
More news
Managers TitleAgeSince
Chief Operating Officer - 16-02-29
Chief Tech/Sci/R&D Officer - 17-09-12
Corporate Officer/Principal - -
More insiders
Veloxis Pharmaceuticals A/S is a Denmark-based commercial-stage specialty pharmaceutical Company. The Company’s product Envarsus XR (tacrolimus extended-release tablets) is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant. It is based upon the Company’s patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The Company operates in the United States through its subsidiary, Veloxis Pharmaceuticals Inc.
More about the company